Published in Oncoimmunology on May 13, 2016
Patient's Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers. Front Immunol (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med (2002) 4.32
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood (2010) 2.41
Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial. Clin Cancer Res (2004) 1.92
Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res (2011) 1.91
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol (2015) 1.69
Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer (2008) 1.66
Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res (2011) 1.63
IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res (2011) 1.59
Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res (2013) 1.58
Type I interferons in anticancer immunity. Nat Rev Immunol (2015) 1.57
NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome. Sci Transl Med (2013) 1.12
Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Sci Transl Med (2015) 1.09
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology (2015) 1.06
Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma. Cancer Res (2013) 1.05
The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. Am J Respir Crit Care Med (2015) 1.02
NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol (2005) 1.01
NK cells and T cells cooperate during the clinical course of colorectal cancer. Oncoimmunology (2014) 0.95
Metabolic perturbation sensitizes human breast cancer to NK cell-mediated cytotoxicity by increasing the expression of MHC class I chain-related A/B. Oncoimmunology (2015) 0.93
Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort. Oncoimmunology (2013) 0.92
Tumor microenvironment in NSCLC suppresses NK cells function. Oncoimmunology (2012) 0.91
Immune signature of tumor infiltrating immune cells in renal cancer. Oncoimmunology (2015) 0.91
Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade. Oncoimmunology (2014) 0.88
B7-H6 expression in non-small cell lung cancers. Int J Clin Exp Pathol (2014) 0.87
CD11b(-)CD27(-) NK cells are associated with the progression of lung carcinoma. PLoS One (2013) 0.85
Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering. Cancer Res (2013) 0.84
B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. Oncoimmunology (2015) 0.84
Impaired zeta chain expression and IFN-gamma production in peripheral blood T and NK cells of patients with advanced lung cancer. Oncol Rep (2009) 0.82
Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse. Oncoimmunology (2014) 0.81
Natural Killer cell control of BRAF(V600E) mutant melanoma during targeted therapy. Oncoimmunology (2015) 0.80
Expression of the c-raf protooncogene in human hematopoietic cells and cell lines. Blood (1987) 0.80
IFNα induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia. Oncoimmunology (2014) 0.79
A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study. Anticancer Res (2013) 0.79
When unity makes strength: Combinatorial NK cell-based immunotherapies against melanoma. Oncoimmunology (2014) 0.77
Impact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial. PLoS One (2015) 0.77
When breast cancer cells start to fend the educational process of NK cells off. Oncoimmunology (2013) 0.76